Tag: Pharmaceuticals
Back to 2012: The Seventh Circuit’s Reliance on Pre-Actavis Law in...
By Michael A. Carrier*
2012 was a long time ago. Barack Obama was in the middle of his two terms as President. Hurricane Sandy...
South Korean Regulator Fines AstraZeneca and Local Firm for Collusion
On Thursday, October 13, the Korea Fair Trade Commission (KFTC) announced that it had fined pharmaceutical giant AstraZeneca and local generic pharmaceutical company Alvogen...
Patent Law Considerations For Drug Discovery Innovations Utilizing Artificial Intelligence
Taking a drug to market is a complex process that involves prediction of one or more combinations of molecules that can be transformed into...
Pharmaceutical Settlements and Judicial Error
The intersection of patent and antitrust law presents challenges for courts. Some of the most complex issues have arisen in the pharmaceutical industry. What...
A Simple Solution to the Problem of ‘Product Hopping’
By Michael A. Carrier (Rutgers Law School)
Brand-name drug companies frequently switch from one version of a drug to another. Sometimes, the switch is made...
European Commission and National Authorities Take a Stand Against Excessive Pricing...
By: Hendrik Viaene and Karolien Van der Putten (Antitrust Alert)
The European Commission and national competition authorities (NCAs) are very actively fighting a number of anticompetitive practices in...
EU Court of Justice Rules on Lundbeck Patent Settlement Agreements
On March 25, 2021, the Court of Justice of the European Union published its judgments in the Lundbeck case. The CJEU dismissed the parties’...
The No Kill Zone: The Other Side of Pharma Acquisitions
In recent years there have been calls for increased scrutiny and enforcement of acquisitions by incumbent pharmaceutical firms of potentially competitive pipeline products. A...
Pay-For-Delay: Who Does the Generic Industry Lobby Represent?
The generic industry lobby, Association for Accessible Medicines (“AAM”), often represents the public interest. In the pharmaceutical industry, it challenges brand drug companies’ anticompetitive...
First of All, Do No Harm: New Directions in EU Antitrust...
The recent Paroxetine and CMA v. Pfizer/Flynn cases confirm the EU approach to pay-for-delay, respectively establish a workable approach to excessive pharmaceutical pricing at...
